Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study, Invest New Drugs 2006 Oct 13 [Epub ahead of print] (2) Y.
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study, Invest New Drugs 2006 Oct 13 [Epub ahead of print] (2) Y.
uk West Japan Thoracic Oncology Group, JAPAN Contact: Kenji Eguchi, Shinichiro Nakamura Telephone: +81-463-93-1121 The GLCC is sponsored by AstraZeneca See body of release for contact details
es - West Japan Thoracic Oncology Group Contact: Kenji Eguchi, Shinichiro Nakamura Telephone: +81 463 93 1121 This initiative has been sponsored by a grant from AstraZeneca For more information, please contact one of the following organisations: - Alliance for Lung Cancer Advocacy, Support, and Education (ALCASE), Contact: Janet Healy, Advocacy Program Manager, Telephone: +1 800-298-2436, e-mail: jmhealy@alcase.
es -- West Japan Thoracic Oncology Group Contact: Kenji Eguchi, Shinichiro Nakamura Telephone: +81 463 93 1121 CONTACT: Janet Healy, Advocacy Program Manager of Alliance for Lung Cancer Advocacy, Support, and Education (ALCASE United States), +1-800-298-2436, jmhealy@alcase.
